Overview

STILDEP: Zolpidem in Depressive and Dysthimic Patients

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Primary objective: To show that the combination of Zolpidem + antidepressant therapy is more effective in the treatment of the secondary insomnia of depressive and dysthimic patients than antidepressant therapy alone in the acute phase of the disease.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Zolpidem